Personalis

United States
New Lisbon, Wisconsin, United States, 94025

Company profile

Personalis company profile

Personalis combines both the technology of sequencing and interpretation, with an extensive history of peer-reviewed publication and commercial success. It is providing an extensive molecular view of a patient’s tumor and characterizes its interplay with the immune system. It aids in the development of safer, effective precision cancer therapies, immunotherapies, and personalized medicines.

Business identity

Contact email
[email protected]
Phone number
+1 650 752 1301
Operating status
Active
Company type
For Profit
Employee range
101-250 employees
Revenue range
$50,000+
Founded
2011-08-01

Headquarters

Postal code
94025
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
6
Total equity funding
$311.2M
Last funding
Post IPO Equity / $50M / 2024-12-19
Last equity funding
Post IPO Equity / $50M
Investors
7
Lead investors
4
Founders
4
Articles
258
Exited on
2019-06-20

Founders and investors

Founders

Atul ButteEuan AshleyMichael SnyderRuss B. Altman

Lead investors

AbingworthLightspeed Venture PartnersMerckTempus

Investors

AbingworthLightspeed Venture PartnersMerckStanford UniversityTempus